Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 30;30(1):218–228. doi: 10.1038/s41591-023-02660-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 7 — a, ROC curve analysis of 2-year EFS rate by %regression-PT for patients treated with nivolumab plus chemotherapy. AUC = 0.76, similar to that for %RVT-PT. b, ROC curve analysis of 2-year EFS rate by %regression + necrosis-PT for patients treated with nivolumab plus chemotherapy; points are labeled as ‘(%regression-PT, %necrosis-PT)’. Addition of %necrosis-PT to %regression-PT did not increase AUC. c, ROC curve analysis of 2-year EFS rate by %regression-PT for patients treated with chemotherapy. d, ROC curve analysis of 2-year EFS rate by %regression + necrosis-PT for patients treated with chemotherapy; points are labeled as ‘(%regression-PT, %necrosis-PT)’. Considering necrosis may be a tumor-intrinsic parameter, it was combined with %RVT-PT in patients receiving nivolumab plus chemotherapy (e), and in patients receiving chemotherapy (f). However, %RVT + necrosis-PT did not greatly alter the AUC achieved with %RVT-PT alone. Points are labeled as ‘(%RVT-PT, %necrosis-PT)’. Nivolumab plus chemotherapy arm, n = 141; chemotherapy arm, n = 126. EFS denotes event-free survival; PT, primary tumor; ROC, receiver operating characteristic; RVT, residual viable tumor. ^aThe solid square is the optimal cutoff, which is the difference between the true positive rate and false positive rate over all possible cutoff values.